- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02178748
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (TB036)
A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective vaccine is a global health priority.
Over a billion people worldwide are infected with one or more helminths. Helminths are parasitic worms, of which Schistosoma mansoni is one species. There is some evidence that helminth infection may affect a person's response to a vaccine. In this trial the investigators hope to investigate whether Schistosoma mansoni infection affects adolescents' responses to a candidate TB vaccine called MVA85A, as adolescents are a crucial target group for an effective TB vaccine.
Studienübersicht
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Entebbe, Uganda
- MRC/UVRI Uganda Research Unit on AIDS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Participants must meet all of the following criteria to enter the trial:
- Healthy adolescents aged 12-17 years (both male and female)
- Resident in the study area for the duration of the study period
- Confirmation of prior vaccination with BCG not less than 6 months prior to projected study vaccination date (by visible BCG scar on examination or written documentation)
- No relevant findings in medical history or on physical examination
- Written informed consent by parent or guardian
- Written informed assent by subject
- Refrain from blood donation during the trial
- Agree to avoid pregnancy for the duration of the trial (female only)
- Able and willing (in the Investigator's opinion) to comply with all the study requirements
- Stool sample negative for S. mansoni (group 1) or positive for S. mansoni infection (group 2), based on the results of the Kato Katz stool analysis
- Willing to delay treatment for schistosomiasis for at least one month (group 2)
Exclusion Criteria
Participants may not enter the trial if ANY of the following apply:
- Clinical, radiological, or laboratory evidence of current active TB disease
- Laboratory evidence at screening of latent M. tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens
- Previous treatment for active or latent tuberculosis infection
- Shared a residence within one year prior to day 0 with an individual on anti-tuberculosis treatment or with culture or smear-positive pulmonary tuberculosis
- Received a TST within 90 days prior to day 0
- Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness, drug or alcohol abuse
- History of serious psychiatric condition or disorder
- Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents within 2 months prior to enrolment
- History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study vaccine, including eggs
- Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the volunteer in the study
- Positive HBsAg, HCV or HIV antibodies
- Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccine for 30 days prior to dosing with the study vaccine, or planned use during the study period
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
- Female currently lactating, confirmed pregnancy or intention to become pregnant during the trial period
- Screening blood sample positive for malaria or Mansonella perstans by microscopy
- Schistosoma mansoni infection intensity greater than 2000 eggs per gram of stool
- Any of the three screening stool samples positive for any helminths on Kato Katz examinations or for S. mansoni or Strongyloides stercoralis by PCR (group 1); or any of the three screening stool samples positive for helminths other than S. mansoni on Kato Katz examinations or for Strongyloides stercoralis by PCR (group 2)
- Screening urine sample positive for S. mansoni infection (group 1)
- Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group 1
Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection.
Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
|
Single dose of 1x10^8pfu MVA85A intramuscular vaccination
Andere Namen:
|
Experimental: Group 2
Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection.
Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
|
Single dose of 1x10^8pfu MVA85A intramuscular vaccination
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
T cell immunogenicity by gamma-interferon ELISPOT of Ag85A response.
Zeitfenster: 8 weeks
|
To compare T cell immunogenicity in adolescents with and without S. mansoni infection.
|
8 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Evaluation of cytokines in supernatant of stimulated cells using Luminex and flow cytometry of Ag85A response.
Zeitfenster: 8 weeks
|
Effects of S. mansoni infection on other aspects of the immune response following MVA85A immunisation.
|
8 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Actively and passively collected data on adverse events.
Zeitfenster: 8 weeks
|
To assess the safety of MVA85A vaccination in BCG-vaccinated African adolescents aged 12-17 years.
|
8 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Alison Elliot, MRC/UVRI and LSHTM Uganda Research Unit
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM. Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018.
- Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TB036
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tuberkulose
-
François SpertiniUniversity of OxfordAbgeschlossenTuberkulose | Mycobacterium Tuberculosis, Schutz vorSchweiz
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktiv, nicht rekrutierendMycobacterium Tuberculosis-InfektionGabun, Kenia, Südafrika, Tansania, Uganda
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenKnochen- und osteoartikuläre Infektion aufgrund von MDR M. Tuberculosis-StämmenFrankreich
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); WalimuRekrutierungTuberkulose, Lungen | Mycobacterium Tuberculosis-InfektionUganda
-
Global Alliance for TB Drug DevelopmentAbgeschlossenTuberkulose | Tuberkulose, Lungen | Lungenkrankheit | Multiresistente Tuberkulose | Arzneimittelsensitive Tuberkulose | Arzneimittelresistente Tuberkulose | Mycobacterium Tuberculosis-InfektionVereinigte Staaten
-
Global Alliance for TB Drug DevelopmentAbgeschlossenTuberkulose | Tuberkulose, Lungen | Lungenkrankheit | Multiresistente Tuberkulose | Arzneimittelsensitive Tuberkulose | Arzneimittelresistente Tuberkulose | Mycobacterium Tuberculosis-InfektionVereinigte Staaten
Klinische Studien zur MVA85A
-
University of OxfordImaxioAbgeschlossenTuberkulose (TB)Vereinigtes Königreich
-
University of OxfordAbgeschlossenTuberkuloseVereinigtes Königreich
-
University of OxfordAbgeschlossen
-
University of OxfordUniversity of BirminghamBeendetTuberkuloseVereinigtes Königreich
-
University of OxfordAbgeschlossen
-
University of OxfordUniversity of BirminghamAbgeschlossenTuberkuloseVereinigtes Königreich
-
University of OxfordAbgeschlossen
-
University of OxfordAbgeschlossen
-
University of OxfordMRC/UVRI and LSHTM Uganda Research UnitAbgeschlossen
-
University of OxfordAbgeschlossen